Table 3.
Body mass index‐adjusted hazard ratios for clinical outcomes depending on body composition
| Model 1 | P‐value | Model 2BMI | P‐value | |
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Overall survival | ||||
| SMI* | 0.84 (0.77, 0.93) | 0.001 | 0.97 (0.86, 1.10) | 0.624 |
| SFI* | 0.84 (0.76, 0.93) | 0.001 | 1.09 (0.92, 1.28) | 0.318 |
| VFI* | 0.89 (0.82, 0.97) | 0.015 | 1.14 (1.00, 1.30) | 0.054 |
| Progression‐free survival | ||||
| SMI* | 0.89 (0.81, 0.97) | 0.008 | 0.95 (0.85, 1.07) | 0.392 |
| SFI* | 0.92 (0.84, 1.00) | 0.058 | 1.08 (0.94, 1.25) | 0.270 |
| VFI* | 0.97 (0.90, 1.06) | 0.505 | 1.18 (1.04, 1.33) | 0.008 |
*
Per 1 standard deviation increasing.
Model 1: adjusted for age, smoking status, ECOG PS, Charlson co‐morbidity index, neutrophil‐to‐lymphocyte ratio, histology, PD‐L1 expression status, treatment agents, and line of treatment. Model 2BMI: Model 1 + BMI.
BMI, body mass index; ECOG PS, European Cooperative Oncology Group Performance Status; SFI, subcutaneous fat index; SMI, skeletal muscle index; VFI, visceral fat index.